Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd (GLENMARK) last traded at ₹2,393, a market capitalisation of ₹67,534 crore, on a P/E of 21.6. Over the past 52 weeks the stock has ranged between ₹1,793 and ₹2,474. Glenmark Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹4,018 crore and net profit of ₹483 crore. Glenmark Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Glenmark Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Glenmark Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4,018 cr, up 23.1% from ₹3,264 cr a year earlier. Net profit was ₹483 cr, up 927.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating profit | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% |
| Other income | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 |
| Interest | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net profit | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS (₹) | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Glenmark Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 17,737 |
| Operating profit | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 4,797 |
| OPM % | 19% | 19% | 14% | 10% | 18% | 27% | 27% |
| Net profit | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,798 |
| EPS (₹) | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 63.71 |
TTM is the trailing twelve months to the most recent quarter.
Glenmark Pharmaceuticals Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 9%
- 3 Years
- 14%
- TTM
- 33%
- 10 Years
- 12%
- 5 Years
- 19%
- 3 Years
- 61%
- TTM
- 134%
- 10 Years
- 11%
- 5 Years
- 36%
- 3 Years
- 48%
- 1 Year
- 22%
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- -3%
- Last Year
- 24%
Glenmark Pharmaceuticals Ltd shareholding pattern
Promoters held 46.65% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.89% and DIIs 18.60%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.64% | 46.64% | 46.65% | 46.65% | 46.65% |
| FIIs | 23.05% | 23.51% | 23.15% | 20.62% | 20.73% | 19.20% | 20.35% | 20.89% |
| DIIs | 13.21% | 13.85% | 14.60% | 17.64% | 18.61% | 20.09% | 19.28% | 18.60% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public | 17.06% | 15.96% | 15.56% | 15.05% | 13.97% | 14.02% | 13.70% | 13.81% |
| No. of shareholders | 1,93,949 | 1,95,059 | 1,92,724 | 1,90,210 | 1,98,789 | 2,01,584 | 1,96,105 | 2,11,418 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Glenmark Pharmaceuticals Ltd
When is Glenmark Pharmaceuticals Ltd’s AGM?
Glenmark Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026.
- AGM48th Annual General Meeting and dividend declaration
See the full results calendar for every Indian company reporting in the next 30 days.
Glenmark Pharmaceuticals Ltd corporate filings
- Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in three…
Read the full analysis - Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/sprayCompany Updatemedium impact
Cruxal's analysis: Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug…
Read the full analysis - Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has issued a public notice regarding its 48th Annual…
Read the full analysis - Letter to Shareholders whose email address are not registered providing the web link of Annual ReportCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued a communication to shareholders who have not…
Read the full analysis - Business Responsibility and Sustainability Reporting (BRSR)Otherslow impact
Cruxal's analysis: Glenmark Pharmaceuticals has filed its Business Responsibility and Sustainability Report…
Read the full analysis - Reg. 34 (1) Annual Report.Otherslow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued the notice for its 48th Annual General Meeting, which…
Read the full analysis - Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26AGM/EGMlow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has scheduled its 48th Annual General Meeting for…
Read the full analysis - Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has submitted a disclosure regarding a settlement agreement in…
Read the full analysis - Intimation of Allotment of shares under the Employee Stock Option Plan 2016Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has completed an allotment of shares pursuant to the exercise of…
Read the full analysis - Intimation of Schedule of Analyst / Institutional Investor MeetingsCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued an intimation regarding upcoming meetings with…
Read the full analysis - Newspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has announced its 48th Annual General Meeting (AGM) to…
Read the full analysis - Transcript of the Earnings CallCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has filed the transcript of its earnings call held on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Glenmark Pharmaceuticals Ltd
Cruxal reads every Glenmark Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.